Named after founder Paul M. Zoll, M.D., a pioneer in cardiac pacing and defibrillation, ZOLL Medical was built on a strong foundation of clinical care and innovation that has continued for three decades. A world leader in resuscitation and critical care technologies, ZOLL has steadily developed and offered best-in-class, technically superior products to offer the world’s most integrated system of resuscitation solutions, as well as complementary products and services in data management and temperature management.
ZOLL Medical Corporation, a leader in medical products and software solutions, helps responders manage, treat, and save lives in emergency rescues and in hospitals; outside the hospital while at work or home; in doctors' and dentists' offices, schools, clinics, nursing homes and other public places; in disaster situations and on the battlefield. ZOLL's products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation contribute to managing patient care and savings lives, as well as increasing the efficiency of emergency medical, fire and hospital operations around the globe. ZOLL also designs and markets software that automates data documentation and management for both clinical and non-clinical information. ZOLL develops and manufactures its products in the United States in California, Chicago, Colorado, Massachusetts, Pittsburgh, and Rhode Island. Its direct sales forces and distributors are located around the world, where its products are sold in more than 140 countries. For more information, visit www.zoll.com
ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that its fully integrated portfolio of resuscitation devices and data management solutions are uniquely capable of helping customers achieve the new recommendations of the 2015 AHA Guidelines. Key changes to the 2015 Guidelines include: · Establishing even more specific targets for depth and rate of chest compressions · Calling for measurement of CPR quality as part of a system of care · Emphasizing the need for real-time CPR feedback to reliably determine CPR quality · Established recommendation for the new ResQCPR® System · Expanding recommendation for cooling for comatose patients post ROSC Increasing the quality of CPR has been an ongoing commitment of ZOLL’s since 2002, when it was the first to introduce real-time CPR feedback in its AED Plus® . Today, all ZOLL defibrillators, including the AED Plus, the R Series® , the X Series® , and the Propaq® MD, feature Real CPR Help® audio and visual feedback for the correct rate, depth, release, and tracking of idle time. Additionally, the 2015 Guidelines recommend automated CPR devices, including the AutoPulse®Resuscitation System, as Class IIb, citing their role in performing high-quality CPR when manual CPR is difficult to achieve, such as during patient transport or in the cath lab. ZOLL’s new ResQCPR System, the first and only CPR device indicated to improve survival from sudden cardiac arrest, was also recommended as Class IIb. ZOLL’s RescueNet® Case Review and RescueNet Code Review services enable systems to allow for real-time debriefing and ongoing monitoring of the quality of CPR as part of a system of care. The new Guidelines expand the recommendation for post ROSC cooling to include all comatose patients, regardless of rhythm or location or arrest. ZOLL’s Thermogard XP® Temperature Management System is uniquely capable of helping hospitals achieve precise temperature control for any recommended target between 32°C and 36°C. “We are very happy that the AHA has taken such a strong position on the need for comprehensive CPR feedback and monitoring of CPR quality,” says Jonathan A. Rennert, President of ZOLL. “These new Guidelines raise the bar for EMS and hospital caregivers, and will help improve survival rates from sudden cardiac arrest.”
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.FOR MEDIA CONTACT: Name : Diane Egan Designation : Marketing Manager, Public Access, Asia Pacific Phone Number : +1 (978) 421-9637 Email : email@example.com
|Mr. Tim McGough discussed the Science of CPR|
Solutions that Strengthen the Chain of Survival Advances in resuscitation are linked to providing rescuers with superior products that work together to improve outcomes. ZOLL has delivered many product innovations and “firsts” that have become standards of care: External non-invasive pacing. Multi-function electrodes. Single-cable monitoring, pacing, and defibrillation. The only biphasic waveform reviewed by the FDA and allowed to have a claim of superiority to monophasic*. A full-rescue AED with CPR help and electronic code data for review and analysis. ECG filtering to minimize CPR interruptions. Electrode compatibility. A revolutionary cardiac support pump that uses a unique load-distributing band. A wearable defibrillator. A miniature pump for fluid resuscitation. Over the years ZOLL has continued to add capabilities, such as powerful and precise intravascular temperature management, and robust data management and analysis software that delivers complete end-to-end resuscitation information. One of ZOLL’s latest innovations will bring together for the first time real-time clinical information to caregivers throughout the continuum of emergency care by integrating data from multiple sources. ZOLL’s Broad Product Portfolio Supports Every Link in the Chain of Survival Early Intervention,